- Home
- RBOT vs ADAG Comparison
RBOT vs ADAG Comparison
Compare RBOT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | ADAG |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RBOT | ADAG |
|---|---|---|
| Price | $1.95 | $1.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 164.0K | 53.1K |
| Earning Date | 11-12-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.83 | $1.30 |
| 52 Week High | $18.97 | $3.16 |
Technical Indicators
Market Signals| Indicator | RBOT | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 26.98 | 48.48 |
| Support Level | $2.16 | $1.76 |
| Resistance Level | $2.33 | $1.93 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 11.29 | 48.94 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.